Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics Inc. (MCRB)
:MCRB
RESEARCH TOOLSreports
Holding MCRB?
Track your performance easily
MCRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.54 - $1.53
Previous CloseN/A
Volume457.00K
Average Volume (3M)2.34M
Market Cap
$125.49M
Enterprise Value$171.21M
Total Cash (Recent Filing)$193.24M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Mar 11, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding170,738,070
10 Day Avg. Volume2,211,117
30 Day Avg. Volume2,343,916
Standard Deviation0.83
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1960.82
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue2.68K
Enterprise Value/Gross Profit1.36
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$10.00Price Target Upside1198.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Seres Therapeutics News
PremiumCompany Announcements
Seres Therapeutics Strengthens Future with VOWST Sale
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessSER-155 hit the primary objective of demonstrating safety with no treatment-emergent serious adverse events in the clinical study.
Financial PerformanceThe sale of Vowst rights to Nestle resulted in significant net proceeds and future milestone payment opportunities.
Regulatory ApprovalBreakthrough therapy designation for SER-155 should speed development and boost partnership options.
Bears Say
Growth ProspectsIt is difficult to find a near-term fundamental growth driver to help improve subdued sentiment on shares.
Pipeline SkepticismThe pipeline at Seres is considered a 'show-me' story, suggesting skepticism about its potential without proven results.
Program UncertaintyThere is a lack of definitive catalysts for the program, with future trial design and guidance needed to better assess the value of the program.
---
Ownership Overview
0.53% Insiders
12.00% Mutual Funds
0.03% Other Institutional Investors
83.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MCRB FAQ
What was Seres Therapeutics Inc.’s price range in the past 12 months?
Seres Therapeutics Inc. lowest stock price was $0.54 and its highest was $1.53 in the past 12 months.
What is Seres Therapeutics Inc.’s market cap?
Seres Therapeutics Inc.’s market cap is $125.49M.
When is Seres Therapeutics Inc.’s upcoming earnings report date?
Seres Therapeutics Inc.’s upcoming earnings report date is Mar 11, 2025 which is in 48 days.
How were Seres Therapeutics Inc.’s earnings last quarter?
Seres Therapeutics Inc. released its earnings results on Nov 13, 2024. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.658.
Is Seres Therapeutics Inc. overvalued?
According to Wall Street analysts Seres Therapeutics Inc.’s price is currently Undervalued.
Does Seres Therapeutics Inc. pay dividends?
Seres Therapeutics Inc. does not currently pay dividends.
What is Seres Therapeutics Inc.’s EPS estimate?
Seres Therapeutics Inc.’s EPS estimate is -0.2.
How many shares outstanding does Seres Therapeutics Inc. have?
Seres Therapeutics Inc. has 170,738,070 shares outstanding.
What happened to Seres Therapeutics Inc.’s price movement after its last earnings report?
Seres Therapeutics Inc. reported an EPS of $0.58 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -10.606%.
Which hedge fund is a major shareholder of Seres Therapeutics Inc.?
Among the largest hedge funds holding Seres Therapeutics Inc.’s share is Flagship Pioneering Inc.. It holds Seres Therapeutics Inc.’s shares valued at 22M.
---
Seres Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (1198.70% Upside)
$10.00 (1198.70% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.54%
12-Months-Change
Fundamentals
Return on Equity
-3758.21%
Trailing 12-Months
Asset Growth
-51.39%
Trailing 12-Months
Company Description
Seres Therapeutics Inc.
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
---
MCRB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress with SER-155 and financial restructuring through the sale of VOWST, positioning the company for future growth. However, the increased net loss and reduction in workforce present notable challenges.Read More>---
MCRB Stock 12 Month Forecast
Average Price Target
$10.00
▲(1198.70% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering MCRB
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+118.20%
reiterated a sell rating 5 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +118.20% per trade.
---